5F-CUMYL-PEGACLONE

5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB₁ receptor. ^[1][2] It appears to be more toxic than related compounds such as CUMYL-PEGACLONE, and has been linked to numerous serious adverse reactions, some fatal.^[3]

5F-CUMYL-PEGACLONE

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Under Psychoactive Substances Act
Identifiers
IUPAC name 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-(5-fluoropentyl)-1H-pyrido[4,3-b]indol-1-one
CAS Number	2377403-49-9
PubChem CID	134818048
ChemSpider	73962276
UNII	7S7IFQ9PPG
Chemical and physical data
Formula	C25H27FN2O
Molar mass	390.502 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(c1ccccc1)N4C=Cc3n(CCCCCF)c2ccccc2c3C4=O
InChI InChI=1S/C25H27FN2O/c1-25(2,19-11-5-3-6-12-19)28-18-15-22-23(24(28)29)20-13-7-8-14-21(20)27(22)17-10-4-9-16-26/h3,5-8,11-15,18H,4,9-10,16-17H2,1-2H3 Key:SMRRORRDOWXERZ-UHFFFAOYSA-N

See also

• 5F-CUMYL-PINACA
• CUMYL-5F-P7AICA